Literature DB >> 16484692

The importance of reporting patient recruitment details in phase III trials.

James R Wright1, Sarah Bouma, Ian Dayes, Jonathan Sussman, Marko R Simunovic, Mark N Levine, Tim J Whelan.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16484692     DOI： 10.1200/JCO.2005.02.6005

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  14 in total

1.  Endorsement of CONSORT by Chinese medical journals: a survey of "instruction to authors".

Authors:  Lu Xiao; Jing Hu; Li Zhang; Hong-cai Shang
Journal:  Chin J Integr Med       Date:  2014-06-28       Impact factor: 1.978

2.  Predicting Participation in Psychiatric Randomized Controlled Trials: Insights From the STEP-BD.

Authors:  Alisa B Busch; Yulei He; Katya Zelevinsky; Alistair J O'Malley
Journal:  Psychiatr Serv       Date:  2015-03-31       Impact factor: 3.084

3.  Recruitment bias in chronic pain research: whiplash as a model.

Authors:  Jo Nijs; Els Inghelbrecht; Liesbeth Daenen; Said Hachimi-Idrissi; Luc Hens; Bert Willems; Nathalie Roussel; Patrick Cras; Kristien Wouters; Jan Bernheim
Journal:  Clin Rheumatol       Date:  2011-08-19       Impact factor: 2.980

4.  Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan.

Authors:  Emi Matsuo; Yasushi Miyazaki; Chizuko Tsutsumi; Yoriko Inoue; Reishi Yamasaki; Tomoko Hata; Takuya Fukushima; Hideki Tsushima; Daisuke Imanishi; Yoshitaka Imaizumi; Masako Iwanaga; Mari Sakai; Koji Ando; Yasushi Sawayama; Daisuke Ogawa; Yasuhisa Kawaguchi; Kazuhiro Nagai; Kunihiro Tsukasaki; Shuichi Ikeda; Yukiyoshi Moriuchi; Shinichiro Yoshida; Miyuki Honda; Jun Taguchi; Yasuyuki Onimaru; Takeshi Tsuchiya; Masayuki Tawara; Sunao Atogami; Masaomi Yamamura; Hisashi Soda; Yoshiharu Yoshida; Yuji Matsuo; Hiroaki Nonaka; Tatsuro Joh; Yumi Takasaki; Chiyuki Kawasaki; Saburo Momita; Itsuro Jinnai; Kazutaka Kuriyama; Masao Tomonaga
Journal:  Int J Hematol       Date:  2007-02       Impact factor: 2.490

5.  A review of reporting of participant recruitment and retention in RCTs in six major journals.

Authors:  Merran Toerien; Sara T Brookes; Chris Metcalfe; Isabel de Salis; Zelda Tomlin; Tim J Peters; Jonathan Sterne; Jenny L Donovan
Journal:  Trials       Date:  2009-07-10       Impact factor: 2.279

6.  Using an automated recruitment process to generate an unbiased study sample of multiple sclerosis patients.

Authors:  Deborah M Miller; R Fox; A Atreja; S Moore; J-C Lee; A Z Fu; A Jain; W Saupe; S Chakraborty; M Stadtler; R A Rudick
Journal:  Telemed J E Health       Date:  2010 Jan-Feb       Impact factor: 3.536

7.  Diagnostic Assessment of Assumptions for External Validity: An Example Using Data in Metastatic Colorectal Cancer.

Authors:  Michael A Webster-Clark; Hanna K Sanoff; Til Stürmer; Sharon Peacock Hinton; Jennifer L Lund
Journal:  Epidemiology       Date:  2019-01       Impact factor: 4.822

8.  Representativeness of two sampling procedures for an internet intervention targeting cancer-related distress: a comparison of convenience and registry samples.

Authors:  Jason E Owen; Erin O'Carroll Bantum; Kevin Criswell; Julie Bazzo; Amanda Gorlick; Annette L Stanton
Journal:  J Behav Med       Date:  2013-05-04

9.  An institutional strategy to increase minority recruitment to therapeutic trials.

Authors:  Victoria V Anwuri; Lannis E Hall; Katherine Mathews; Brian C Springer; Jennifer R Tappenden; Dione M Farria; Sherrill Jackson; Melody S Goodman; Timothy J Eberlein; Graham A Colditz
Journal:  Cancer Causes Control       Date:  2013-07-12       Impact factor: 2.506

10.  Endorsement of the CONSORT statement by high-impact medical journals in China: a survey of instructions for authors and published papers.

Authors:  Xiao-qian Li; Kun-ming Tao; Qing-hui Zhou; David Moher; Hong-yun Chen; Fu-zhe Wang; Chang-quan Ling
Journal:  PLoS One       Date:  2012-02-13       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.